💊 AI-driven Drug Discovery

Today's Highlights

Atomwise - revolutionizing the pharmaceutical landscape

AI Events - upcoming events in the AI world

In Other News - a few interesting developments we're tracking

Atomwise - revolutionizing the pharmaceutical landscape

Atomwise is a pioneering company in the realm of artificial intelligence (AI)-driven drug discovery. The company's goal is to transform small molecule drug development, with a focus on 'undruggable' targets that were previously unreachable by conventional techniques.

The patented AI technology behind Atomwise's business, AtomNet®, which uses deep learning algorithms for structure-based drug development, is at the company's foundation. The development of new medications has been greatly accelerated due to AtomNet®'s role in the discovery and optimization of new compounds which seek complex biological targets. With more than 250 global partners, Atomwise works with numerous organizations in the pharmaceutical, agricultural, and developing biotechnology industries to address over 600 specific disease targets.

In order to expand its drug research operations, Atomwise has recently entered into a number of high-value partnerships. Notably, in August 2021, a research and development agreement was reached with Sanofi, a major pharmaceutical company. The deal, which might be worth over $1 billion, included paying Atomwise $20 million up front for the discovery, synthesis, and development of lead chemicals that could target up to five different biological entities.

The rise of Atomwise shows how AI has the ability to speed up the drug discovery process and create partnerships throughout the healthcare industry to address urgent medical concerns. Atomwise continues to contribute to the larger objective of delivering better medications quicker through its AI-powered platforms, living up to its motto of "Better medicines faster."

The company was founded in 2012 by Abraham Heifets, Alexander Levy, and Izhar Wallach. To date, they have raised over $174 million.